open access

Vol 88, No 4 (2017)
Research paper
Published online: 2017-04-28
Get Citation

Evaluation of tissue metalloproteinase inhibitor TIMP-1 and Survivin levels during third trimester pregnancy — a preliminary report

Agata Karowicz-Bilińska, Urszula Kowalska-Koprek, Dorota Estemberg, Anita Sikora-Szubert
DOI: 10.5603/GP.a2017.0038
·
Pubmed: 28509321
·
Ginekol Pol 2017;88(4):198-204.

open access

Vol 88, No 4 (2017)
ORIGINAL PAPERS Obstetrics
Published online: 2017-04-28

Abstract

Objectives: A proper implantation of trophoblastic cells and an appropriate metalloproteinases activity is required to cause disintegration of basal membranes of cells. The activity of tissue matrix metaloproteinases can be inhibited by their matrix inhibitors — TIMP-s. Survivin is a member of inhibitor of apoptosis proteins family (IAP), that suppresses caspase activation, influences VEGF expression and promotes proliferative action of endothelial cells.

Material and methods: The aim of the study was to assess concentrations of two independent anti-apoptotic factors. TIMP-1 and survivin in serum of women in their third trimester of pregnancy and in umbilical cord blood of neonates – drawn separately from veins and arteries. The study group consisted of 29 pregnant women in physiological pregnancy and with correct fetal development, in gestational age between 37 to 40 weeks of gestation. Blood used in the study was collected from maternal cubital fossa veins and from neonatal umbilical cords (from veins and from arteries separately). The research was conducted using TIMP-1 and Survivin ELISA kits from R & D Systems according to manufacturers’ recommendations and protocols.

Results: The concentrations of TIMP-1 were similar and independent of the source of blood samples. Arterial values of TIMP-1 in umbilical cord compared to maternal and fetal veins were slightly lower, but no statistical difference was found. The mean concentrations of Survivin were comparable but we found that in some cases the results in cord blood serum in both vessels-vein and arteries were almost negative. Arterial values of Survivin in umbilical cord compared to maternal blood were higher, but no statistical difference was found.

Conclusions: In III-rd trimester of pregnancy parameters of Timp-1 and Survivin — anti-apoptotic substances concentration were similar in maternal and cord blood in both artery and vein. We found no increased activity of selected antiapoptotic factors.

Abstract

Objectives: A proper implantation of trophoblastic cells and an appropriate metalloproteinases activity is required to cause disintegration of basal membranes of cells. The activity of tissue matrix metaloproteinases can be inhibited by their matrix inhibitors — TIMP-s. Survivin is a member of inhibitor of apoptosis proteins family (IAP), that suppresses caspase activation, influences VEGF expression and promotes proliferative action of endothelial cells.

Material and methods: The aim of the study was to assess concentrations of two independent anti-apoptotic factors. TIMP-1 and survivin in serum of women in their third trimester of pregnancy and in umbilical cord blood of neonates – drawn separately from veins and arteries. The study group consisted of 29 pregnant women in physiological pregnancy and with correct fetal development, in gestational age between 37 to 40 weeks of gestation. Blood used in the study was collected from maternal cubital fossa veins and from neonatal umbilical cords (from veins and from arteries separately). The research was conducted using TIMP-1 and Survivin ELISA kits from R & D Systems according to manufacturers’ recommendations and protocols.

Results: The concentrations of TIMP-1 were similar and independent of the source of blood samples. Arterial values of TIMP-1 in umbilical cord compared to maternal and fetal veins were slightly lower, but no statistical difference was found. The mean concentrations of Survivin were comparable but we found that in some cases the results in cord blood serum in both vessels-vein and arteries were almost negative. Arterial values of Survivin in umbilical cord compared to maternal blood were higher, but no statistical difference was found.

Conclusions: In III-rd trimester of pregnancy parameters of Timp-1 and Survivin — anti-apoptotic substances concentration were similar in maternal and cord blood in both artery and vein. We found no increased activity of selected antiapoptotic factors.

Get Citation

Keywords

pregnancy, umbilical cord blood, TIMP-1, Survivin

About this article
Title

Evaluation of tissue metalloproteinase inhibitor TIMP-1 and Survivin levels during third trimester pregnancy — a preliminary report

Journal

Ginekologia Polska

Issue

Vol 88, No 4 (2017)

Article type

Research paper

Pages

198-204

Published online

2017-04-28

DOI

10.5603/GP.a2017.0038

Pubmed

28509321

Bibliographic record

Ginekol Pol 2017;88(4):198-204.

Keywords

pregnancy
umbilical cord blood
TIMP-1
Survivin

Authors

Agata Karowicz-Bilińska
Urszula Kowalska-Koprek
Dorota Estemberg
Anita Sikora-Szubert

References (19)
  1. Bonnema DD, Webb CS, Pennington WR, et al. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007; 13(7): 530–540.
  2. Divya S, Sanjeev S, Tapas KC. Multifaceted role of matrix metalloproteinases (MMPs). Front Mol Biosci. 2015; 2: 19–23.
  3. Hu J, Van den Steen PE, Sang QXA, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007; 6(6): 480–498.
  4. Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2009; 158(3): 983–994.
  5. Koskivirta I, Rahkonen O, Mäyränpää M, et al. Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. Histochem Cell Biol. 2006; 126(3): 335–342.
  6. Higa R, Kurtz M, Capobianco E, et al. Altered matrix metalloproteinases and tissue inhibitors of metalloproteinases in embryos from diabetic rats during early organogenesis. Reprod Toxicol. 2011; 32(4): 449–462.
  7. Świerczewski A, Kobos J, Pasiński J, et al. Ekspresja metaloproteinazy MMP-9 oraz tkankowego inhibitora metaloproteinazy TIMP-2 w łożyskach u ciężarnych z wewnątrzmacicznym ograniczeniem wzrastania płodu. Ginekol Pol. 2012; 83: 439–45.
  8. Seval Y, Akkoyunlu G, Demir R, et al. Distribution patterns of matrix metalloproteinase (MMP)-2 and -9 and their inhibitors (TIMP-1 and TIMP-2) in the human decidua during early pregnancy. Acta Histochem. 2004; 106(5): 353–362.
  9. Tamm I, Richter S, Oltersdorf D, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res. 2004; 10(11): 3737–3744.
  10. Doucette T, Latha K, Yang Y, et al. Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas. Neuro Oncol. 2014; 16(9): 1220–1228.
  11. Xu P, Wang Y, Piao Y, et al. Effects of matrix proteins on the expression of matrix metalloproteinase-2, -9, and -14 and tissue inhibitors of metalloproteinases in human cytotrophoblast cells during the first trimester. Biol Reprod. 2001; 65(1): 240–246.
  12. Lee MA, Palace J, Stabler G, et al. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain. 1999; 122 ( Pt 2): 191–197.
  13. Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Anticancer Res. 2000; 20(2B): 1311–1316.
  14. Holten-Andersen M, Christensen IJ, Nilbert M, et al. EORTC-Receptor and Biomarker Group. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study. Eur J Cancer. 2004; 40(1): 64–72.
  15. Niewiarowska K, Pryczynicz A, Dymicka-Piekarska V, et al. Diagnostic significance of TIMP-1 level in serum and its immunohistochemical expression in colorectal cancer patients. Pol J Pathol. 2014; 65(4): 296–304.
  16. Giaginis C, Nikiteas N, Margeli A, et al. Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal cancer patients: associations with clinicopathological variables and patient survival. Int J Biol Markers. 2009; 24(4): 245–252.
  17. Locksmith GJ, Clark P, Duff P, et al. Amniotic fluid concentrations of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during pregnancy and labor. Am J Obstet Gynecol. 2001; 184(2): 159–164.
  18. Tency I, Verstraelen H, Kroes I, et al. Imbalances between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in maternal serum during preterm labor. PLoS One. 2012; 7(11): e49042.
  19. Malamitsi-Puchner A, Baka S, Boutsikou M, et al. Cord blood survivin concentrations in human full-term normal and complicated pregnancies. In Vivo. 2009; 23(1): 139–142.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl